Navigation Links
Emageon Reports Third Quarter 2007 Financial Results
Date:11/6/2007

(http://www.streetevents.com).

Forward Looking Statements. This press release contains forward-looking statements about Emageon that represent the Company's current views with respect to, among other things, future events and financial performance. Any forward-looking statements contained in this press release are based on Emageon's historical performance and on current plans, beliefs and expectations. Actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various risks, uncertainties and other factors beyond its control. These risks, uncertainties and other factors include, among others, the risk that it may not compete successfully against larger competitors, risks associated with its history of operating losses, the risk of loss of its senior executive management, risk associated with expansion of its market and selling efforts into new product segments, the risk that its target markets do not develop as expected, the risk that it may not manage its growth effectively, the risk that its acquisition strategy may fail or that acquisitions could result in integration difficulties, dilution or other adverse financial consequences, the risk of failure to raise additional capital on acceptable terms, risks associated with its reliance on continuing relationships with large customers, the risk of significant product errors or product failures, the risk of its reliance on reseller arrangements for important components of its solution, the risk that it may not respond effectively to changes in its industry, the risk of its customers' reliance on third party reimbursements, and the risk of the potential impact on its business of Food & Drug Administration (FDA) regulations and other applicable health care regulations. Additional information concerning these and other factors that could affect Emageon's financial and operating results may be found u
'/>"/>

SOURCE Emageon Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)... Though the number of jobs created i... companies reported a different kind of slowdown: ...s months. , Seattle, WA (...created in the medical field slowed in June overal...ind of slowdown that will be music to the ears of ...
(Date:7/25/2008)... supporting the US Department of Defense and Feder... Phoenix. Operation Golden Phoenix is a, four-da...ned to assist, federal, state and local agencies w...os. Dataline is providing a vital, ad-hoc, secure ... use during the exercise., NORFOLK, Va., July 25 ...
(Date:7/25/2008)...elationship Based on Significant Improvements in M...MDdatacor, Inc., a leader in health,care quality m..., today,announced it has entered into a long-term ...rt Wellmark,s Collaboration on Quality(SM) Incent ...ion between Wellmark and,primary care clinicians t...
(Date:7/25/2008)...URG, Ill., July 25 /PRNewswire/ -- Sagent Pharmace...utical company, today announced that it,has launch...arrhythmic,indicated for the treatment and prophyl...ion and hemodynamically unstable ventricular,tachy... heart beat.,Sagent,s amiodarone HCl injection wil...
Breaking Medicine News(10 mins):Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Dataline Announces Participation in Operation Golden Phoenix 2Health News:Dataline Announces Participation in Operation Golden Phoenix 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3
... that there is an increase in number of children c...ers asked for tougher action// to tackle young cri...children under the age of 16 charged for criminal ...0 % in the past year. The crimes include violence,...
...dy language comes easy and our response is often b...phrenia,// may have a difficulty and not be able ...izophrenia, even those who have mild to moderate s...uent in understanding body language, according to ...
...ating in the anti-reservation protest have stated ...e Government rolls back plans for reservation of s...s have collapsed and nearly 300 have been provided...inite strike of resident doctors in five governmen...
... Annual Meeting of the American Society of Hyperte...ween the female sexual dysfunction// (FSD) and hig...d that mostly women with increased hypertension an...ysfunction is defined as persistent or recurring d...
Other Medicine News:Health News:Schizophrenia impairs body language comprehension 2Health News:Schizophrenia impairs body language comprehension 3Health News:Doctors Urge Government To Roll Back Quotas 2Health News:Link Established Between FSD and High Blood Pressure 2
(Date:7/23/2008)... SAN FRANCISCO, July 23 /- InCode Bio... company, today announced preclinical test,results...idate rC3-1 for,the treatment of the rare chronic ... (PNH). The complete results will be presented at ...l, Switzerland, September 28,2008., The only tre...
(Date:7/22/2008)... - Strong efficacy results from a multi-center 293....com , Toronto Stock Exchange Symbol: CYT, MONTR...Technologies,Inc., the global leader in cryotherap...ounced that results previously presented from thre...product, Arctic Front(R),were published earlier t...
(Date:7/22/2008)...Study Demonstrates Feasibility and Efficacy of Tre...ry Liver Cancer, SAN FRANCISCO, and YONGIN-SI, So...(San Francisco, CA and Ottawa, Ontario), and its S...oday that novel findings from,a Phase I clinical t...onstrated that the product was well-tolerated and ...
(Date:7/22/2008)... SOUTH SAN FRANCISCO, Calif., July 22 /PRNewswire/...at it has completed patient enrollment,in its Phas...ability and,ammonia scavenging effects of HPN-100 ...phenylbutyrate) in patients with urea cycle disord...results in the fourth quarter,of this year., (Log...
Breaking Medicine Technology:InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3New Jersey Leaders Join Forces to Battle Chronic Disease 16998 1New Jersey Leaders Join Forces to Battle Chronic Disease 16998 2New Jersey Leaders Join Forces to Battle Chronic Disease 16998 3New Jersey Leaders Join Forces to Battle Chronic Disease 16998 4NYU Medical Center Changes Name to Honor Chairman of Board 26 Wife 4649 1NYU Medical Center Changes Name to Honor Chairman of Board 26 Wife 4649 2NYU Medical Center Changes Name to Honor Chairman of Board 26 Wife 4649 3NYU Medical Center Changes Name to Honor Chairman of Board 26 Wife 4649 4NYU Medical Center Changes Name to Honor Chairman of Board 26 Wife 4649 5Low Vitamin D Levels Linked to Leg Artery Blockages 16994 1Low Vitamin D Levels Linked to Leg Artery Blockages 16994 2Low Vitamin D Levels Linked to Leg Artery Blockages 16994 3Older people are nations happiest 16991 1Older people are nations happiest 16991 2
... in a randomized phase II/III clinical trial,antic...Newswire-FirstCall/ -- Cell,Therapeutics, Inc. (CT...s, which demonstrate that treatment with pixantron... cardiotoxicity, while,doxorubicin and mitoxantron...compared the cardiac side effects of equiactive do...
....--(BUSINESS WIRE)--Jun 26, 2007 - Sirtris,Pharmac... company,focused on discovering and developing sma...unced today that activation of SIRT1, a,member of ...t,against neurodegenerative diseases such as Alzhe...n animal models. These findings,appear in an artic...
Other Medicine Technology:Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 2Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 3Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 4Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 5Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 6Resveratrol Studies Suggest Broad Implications for SIRT1 Activation,in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease 2Resveratrol Studies Suggest Broad Implications for SIRT1 Activation,in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease 3
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
Medicine Products: